US 12,076,302 B2
Dermatologic topical applications of ROR gamma and ROR gamma-t inhibitors for the prevention of skin cancer development
Michael Girardi, Madison, CT (US); and Julia Lewis, Clinton, CT (US)
Assigned to Yale University, New Haven, CT (US)
Appl. No. 17/276,800
Filed by Yale University, New Haven, CT (US)
PCT Filed Sep. 17, 2019, PCT No. PCT/US2019/051482
§ 371(c)(1), (2) Date Mar. 16, 2021,
PCT Pub. No. WO2020/061024, PCT Pub. Date Mar. 26, 2020.
Claims priority of provisional application 62/733,060, filed on Sep. 18, 2018.
Prior Publication US 2021/0353568 A1, Nov. 18, 2021
Int. Cl. A61K 31/165 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/165 (2013.01) [A61K 9/0014 (2013.01); A61K 45/06 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of inhibiting development of a keratinocyte-derived malignancy characterized by mutations in a p53 gene, the method comprising applying repetitively a topical inhibitor of an RAR-related orphan receptor C (RORC) product to skin of an individual in need thereof in sufficient concentration and over sufficient time to inhibit RORC product activity, wherein the topical inhibitor inhibits (i) RORγ, (ii) RORγt, or (iii) RORγ and RORγt.